TJ Cradick
Company: Excision BioTherapeutics Inc.
Job title: Chief Scientific Officer
Bio:
TJ Cradick is the Chief Scientific Officer (CSO) at Excision BioTherapeutics, a clinical-stage biotech company that is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients. With over 20 years of experience in nucleases, genome editing, and gene therapy, TJ leads Excision’s scientific vision and strategy, oversees the research and development of its pipeline projects, and manages collaborations with academic and industry partners. TJ is a recognized leader and innovator in the field of CRISPR/Cas9 technology, having published several influential papers on its applications, mechanisms, and optimization. He is also a Scientific Advisory Board Member at CRISP-HR Therapeutics, Inc. and at Catalytic Data Science. TJ is passionate about advancing the science and practice of CRISPR/Cas9 to address unmet medical needs and transform the lives of patients with viral diseases.
Seminars:
Advanced Bioinformatics for Multiplex Viral Targeting 10:30 am
Dual gRNA excisions on viral DNA In-silico probes to analyze on- and off-target effects Computational methods to design the most effective guide RNAsRead more
day: GENE EDITING INNOVATION discussion day
Chairs Closing Remarks 3:00 pm
day: GENE EDITING INNOVATION discussion day
Chair’s Opening Remarks 9:50 am
day: GENE EDITING INNOVATION discussion day